A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. Known history of severe allergies, or allergy to any component of KL340399;
• •2. Received any previous therapy of STING-activating, or received any immunostimulant therapy within 28 days;
• •3. Have other malignancies within 5 years;
• •4. Concomitant or known metastases to brain or central nervous system;
• •5. Active autoimmune disease;
• •6. History of major cardiovascular diseases;
• •7. Uncontrolled systemic diseases;
• •8. Known of coagulation disorders, hemorrhagic disease;
• •9. Confirmed serious lung disease or lung disease;
• •10. Subjects with third space fluid that can not be controled by drainage or other methods;
• •11. Known active infection;
• •12. Known HIV, active hepatitis B/C virus;
• •13. Pregnant or lactating women;
• •14. Received immunotherapy and had immune related adverse reactions ≥ grade 3;
• •15. Have received stem cell transplantation or organ transplantation;
• •16. Receive any live or attenuated live vaccine within 4 weeks;
• •17. History of serious dementia, altered mental status, or any psychiatric disorder;
• •18. Evidence of alcohol or drug abuse;
• •19. Participated in any other clinical trials and received treatment within 4 weeks;
• •20. Have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study.